The New Threat to Young People's Health: E-Cigarette Experimentation

Aug.31.2022
The New Threat to Young People's Health: E-Cigarette Experimentation
Electronic cigarettes pose a new threat to youth health, as they are difficult to identify and can cause serious health problems.

The health of young people is under a new threat: experimenting with e-cigarettes. These devices are difficult for educators to detect in schools and appear increasingly subtle and enticing with each new release. They are used in backyards, rooms, clubs, schools, and stored in backpacks where they can easily be exchanged among peers without drawing attention.


Stella Martins, a chemical dependency expert in the field of pulmonology at InCor Tobacco Treatment Program (Instituto do Coração, Hospital das Clínicas, FMUSP), has issued a warning stating that there are many counterfeit devices available, some even designed to look like asthma inhalers. This means that adolescents can use them in places like classrooms and restaurants, believing them to be a form of trustworthy treatment.


The Getty Images agency.


The use of electronic cigarettes poses significant risks to individuals, including respiratory illnesses, increased incidence of cardiovascular diseases like heart disease, and even cancer. In the United States, there have been cases of young people seeking medical attention with EVALI (e-cigarette, or vaping, product use-associated lung injury) resulting in injuries including organ damage, permanent disability, lung transplants, and death.


A study conducted by the Bloomberg School of Public Health at Johns Hopkins University has found that electronic cigarettes produced by major tobacco manufacturers contain high levels of caffeine, antibiotics, anti-seizure medications, heart rate control drugs, and significant amounts of caffeine. The investigation also revealed substances used to treat psoriasis, fertilizers, and disinfectants within the enticing aromas and flavors of these products.


Doctors at InCor explain that the new electronic cigarettes contain high levels of nicotine, specifically nicotine salts, which contain new toxins that do not dissipate when inhaled, causing damage to the lungs. "These harmful substances disguise themselves as appealing aromas and flavors, masking any discomfort or irritation in the throat. Nicotine salts pose a new problem and challenge to public health.


Experts warn that young people are able to consume more and more nicotine, as it reaches the brain faster and brings greater pleasure. Inhaling large quantities of substances through e-cigarettes can quickly lead to addiction. "Due to the speed of dependence, use is extremely dangerous, which makes young people want to increase their consumption, and when they try to quit smoking, they will experience many stimuli, anxiety, and strong desires to continue smoking." Currently, users consume the equivalent of one pack of cigarettes per day through electronic cigarettes in just a few weeks. In traditional cigarettes, this would take years to develop.


Doctors have also issued a warning about the black market for counterfeit goods. "The cost of refilling these devices is very high, and in countries where marketing is allowed for economic reasons, many young people ultimately turn to the secret market or switch to traditional cigarettes.


Dr. Stella claims that fragrances used in parallel market products contain dangerous substances, such as THC and Vitamin E acetate, which can lead to the accumulation of fat in the lungs when inhaled, causing damage. Another risk pointed out by Dr. Stella is the hindrance of brain development and maturity, which occurs around the age of 21. The prefrontal cortex of young people's brains has a high concentration of nicotine, which affects decision-making, discernment of right and wrong, organization, and execution of plans.


According to a resolution by the National Health Supervision Bureau in 2009, Brazil prohibits the sale, marketing and promotion of smoking devices. Therefore, enhanced regulation is important. However, parents, educators and guardians need to intervene directly by accompanying users who may not be aware of the risks of this disease, the doctor concluded.


Announcement


This article is compiled from third-party information and is only meant for industry-related exchange and learning.


This article does not represent the viewpoint of 2FIRSTS, and 2FIRSTS cannot confirm the truthfulness and accuracy of the content. The compilation of this article is only intended for communication and research within the industry.


Due to limitations in our translation abilities, there may be discrepancies between the compiled article and the original text. Therefore, please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government in regards to any domestic, issues related to Hong Kong, Macao, and Taiwan, and foreign affairs statements and positions.


Copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us to have it removed.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
UK HMRC Launches Vape Duty Stamps on October 1, Ushering in Supply-Chain Traceability as Chinese Exporters Face New Compliance Hurdles
UK HMRC Launches Vape Duty Stamps on October 1, Ushering in Supply-Chain Traceability as Chinese Exporters Face New Compliance Hurdles
HM Revenue & Customs put the UK's Vaping Products Duty and Vaping Duty Stamps Scheme into effect on October 1. All vaping liquids manufactured in or imported into the UK are now subject to duty at £2.20 per 10ml, regardless of nicotine content. The stamp regime will introduce digital functionality designed to provide traceability throughout the supply chain, with approved manufacturers, importers and warehousekeepers required to report product movements and retailers and consumers eventually able to scan stamps to verify authenticity. China exported $177 million of vape-related products to the UK in August, up 51.4% year over year, increasing the significance of the new compliance regime for China's Shenzhen-centered vape supply chain.
Regulations
Oct.04
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
FOGER has introduced the Switch Pro 30K Nixodine Pod in U.S. retail channels, bringing a 6-methylnicotine (6-MN)-related formulation into its reusable Switch Pro 30K pod ecosystem. The product retains the existing reusable dock and magnetic replacement pod architecture, featuring a 19ml prefilled pod, dual-mesh heating and Normal/Boost modes. The Nixodine version is labeled nicotine-free in terms of conventional nicotine but uses a 5% Nixodine-related formulation. The product has appeared in U.S. retail and wholesale channels, with some listings indicating Kentucky-only availability.
Aug.28
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
California Lawmakers Pass Disposable Nicotine Vape Ban, With Sales Prohibition Set for 2028
California Lawmakers Pass Disposable Nicotine Vape Ban, With Sales Prohibition Set for 2028
According to CBS Los Angeles on August 27, 2026, California lawmakers have passed Assembly Bill 762, which would phase out disposable, battery-embedded nicotine vapes in the state. If signed by Governor Gavin Newsom, manufacturing and importation of the covered products would be prohibited beginning January 1, 2027, followed by a sales ban on January 1, 2028. Driven primarily by concerns over electronic waste, lithium-battery fires and environmental pollution, the legislation would further shift California’s legal vape market toward rechargeable, refillable or replaceable-pod devices.
Aug.28
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
KIWI has launched the Spark 2 and Spark 2 Pro refillable pod systems in Germany at official prices of €18 and €29, respectively. Spark 2 uses an 800mAh removable lithium-ion battery in a pen-style body, while Spark 2 Pro features a 1,400mAh removable battery, a box-shaped design and vibration feedback every 20 puffs. Both devices use the same 2ml Spark V2 pods in 0.8Ω and 1.2Ω versions, with AirSync airflow adjustment and a choice between Cotton Tips and conventional Drip Tips. The new pods also remain compatible with the original KIWI Spark.
News
Sep.29 by 2Firsts Perspectives